A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2 by Szpisjak, László et al.
A novel SETX gene mutation producing ataxia with oculomotor
apraxia type 2
Laszlo Szpisjak1, Izabella Obal1, Jozsef I Engelhardt1, Laszlo Vecsei1,2 , Peter 
Klivenyi1
1 Department of Neurology, University of Szeged, Szeged, Hungary
2 MTA-SZTE Neuroscience Research Group, Szeged, Hungary
Correspondence: Peter Klivenyi, University of Szeged, Department of Neurology, 
Semmelweis u. 6, H-6725 Szeged, Hungary, e-mail: klivenyi.peter@med.u-szeged.hu
Abstract
Aim of the Study: This paper documents a patient with ataxia with oculomotor apraxia
type  2  (AOA2)  caused  by an  SETX mutation  (c.502C>T)  combined with  a  large
SETX deletion (including exons 11-15). 
The first symptoms appeared in a female Caucasian patient at the age of 25, in the
form of deteriorating dexterity, gait instability and dizziness. The diagnostic work-up
demonstrated dysarthria, an extraocular muscle dysfunction, smooth ataxia in all four
limbs and in the trunk, mild pyramidal symptoms with an elevated alpha-fetoprotein
level in the serum and cerebellar atrophy revealed on MRI. The family history was
unremarkable. The diagnosis of AOA2 was confirmed by genetic testing.
Conclusions: We have found a novel SETX gene missense mutation, combination of
which  with  an  extensive  SETX deletion  results  in  AOA2.  The  results  of  clinical,
laboratory, radiographic and genetic tests are described and compared with those of
the cases in the literature.
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Introduction
After  Friedreich’s  ataxia,  ataxia  with  oculomotor  apraxia  type  2  (AOA2)  is  the
second  most  common  autosomal  recessive  inherited  ataxia  in  the  European
population.  This  disease,  which  has  an  early  onset  and  progresses  slowly,  is
characterized  by  cerebellar  symptoms,  oculomotor  apraxia,  axonal  sensorimotor
neuropathy,  a  cognitive  impairment  and  other  neurological  features,  including
pyramidal  symptoms,  involuntary movements  such as  head  tremor,  dystonia  and
chorea  [1,  2].  A typical  laboratory  finding  is  an  elevated  serum alpha-fetoprotein
(AFP)  level.  In  most  of  the  cases,  the  brain  MRI  scans  demonstrate  marked
cerebellar atrophy, mainly in the vermis. The genetic cause of AOA2 is a mutation in
the  SETX gene on chromosome 9q34, which encodes senataxin, a nuclear protein
that has DNA/RNA helicase activity and possibly plays a role in DNA repair and RNA
processing.
This report describes a female Caucasian patient with an AOA2 phenotype with
one novel SETX gene mutation.
Case presentation:
A 28-year-old  female  patient  was  referred  to  our  clinic  with  signs  of  impaired
coordination.  The  first  symptoms  appeared  at  the  age  of  25,  with  dizziness,
imbalance and clumsiness of the hands. Some months later,  her speech became
slower  and  mildly  slurred.  She  also  had  gaze  fixation  difficulty,  with  intermittent
diplopia and blurred vision.
Her  neurological  examination  revealed  mild  overshooting  saccadic  pursuits,
horizontal gaze fixation instability, oculomotor apraxia, slurred speech, smooth ataxia
in all four limbs and in the trunk, brisk tendon reflexes in the lower extremities and
normal  sensory  functions.  She  had  no  other  diseases.  Her  family  history  was
unremarkable. Her parents and her brother did not report any neurological problems
(Figure 1/a).
The routine laboratory findings, including a complete blood count, creatine kinase
and  cholesterol  were  normal.  The serum AFP level  was  elevated,  at  21.9  ng/ml
(normal  <  7.0  ng/ml).  The  brain  MRI  revealed  moderate  cerebellar  atrophy with
normal supratentorial structures (Figure 2). 
Cardiological, diabetological and fundoscopic examinations did not demonstrate
any pathological markers. Genetic testing for Friedreich’s ataxia resulted in normal
GAA repeat numbers (7 and 13 repeats). The cerebellar atrophy seen in the MRI
scan, the elevated AFP serum level and the lack of oculocutaneous telangiectasias
led  to  a  presumed  diagnosis  of  AOA2.  SETX gene  sequencing  analysis  was
therefore performed (Centogene AG, Rostock, Germany). 
Gene  sequencing  identified  a  novel  heterozygous  point  mutation  in  the  gene:
c.502C>T p.Arg168Trp  in  exon 6 (Figure  1/b).  Multiplex ligation-dependent  probe
amplification testing revealed a large heterozygous deletion, including exons 11-15.
The presence of the c.502C>T variant in the ExAC database at a very low frequency
(1/73,152  alleles  in  the  European  population)  and  the  absence  of  homozygous
healthy  individuals,  is  suggestive  its  pathogenic  effect
(http://exac.broadinstitute.org/variant/9-135211899-G-A).  
The identified arginine  tryptophan change caused by the missense mutation is
located  within  a  highly  conserved  region  of  the  protein  senataxin  (Fig.  1/c).  We
presume  that  this  compound  heterozygous  state  is  responsible  for  the  SETX
insufficiency.
We were unable to perform the segregation analysis because the patient’s father
has already died and her closest relatives (mother and brother) did not give their
consent to genetic testing.
Discussion
The majority of the AOA2 mutations reported earlier involved frameshift, missense,
nonsense and splice-site mutations and deletions to various extents in the  SETX
gene. We report here a novel missense mutation and a large deletion in this gene,
observed in a young woman with cerebellar ataxia, oculomotor apraxia, an elevated
serum AFP level and cerebellar atrophy. This missense mutation, located outside the
helicase domain of the protein senataxin, affected the N-terminal domain, while the
extensive deletion gave rise to a truncating protein structure, including loss of the
nuclear localization signal and in part the C-terminal helicase domain [2].
Table 1 presents the major clinical signs of 13 other AOA2 patients with exon 6
mutations [3-6] in comparison with the profile of our patient. Our patient manifested a
later age at onset and brisk tendon reflexes relative to the other AOA2 cases. In our
patient, the milder phenotype and the later onset of disease, compared to classic
AOA2 cases, may be suggestive of a residual activity of SETX due to the hypomorph
missense mutation.
The previous genotype to  phenotype correlations coincide moderately with  the
clinical presentation of our patient. Despite the observation of brisk tendon reflexes in
the lower limbs, pyramidal signs were more prevalent with missense mutations in the
helicase domain. Dystonia was frequent,  primarily with missense mutations in the
helicase domain [2], and the lack of dystonia in our patient is therefore not surprising.
Oculomotor apraxia was present in about half of the literature AOA2 patients, and
also  in  our  patient.  The  elevated  AFP  levels  and  the  cerebellar  atrophy  were
significant diagnostic findings in almost all  AOA2 cases, including our patient. The
earlier studies reported that the phenotype was most severe when the mutation was
missense and located outside the helicase domain, in contrast with the truncating
mutations  and  the  missense  mutations  affecting  the  helicase  domain  [2].  Our
patient’s symptoms are so far mild, possibly because of the compound heterozygous
state and respectively the short time that has elapsed since the onset of the disease.
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Table  1.  Comparison  of  our  patient  with  13  other  AOA2  patients  with  exon  6
mutations of the SETX gene [3-6]
Data on 13 previously reported
patients with exon 6 mutations
Our patient
Age at onset (years) Mean: 12.7 25
Initial signs
Ataxia:11/13 cases
AtaxiaDysarthria: 3/13 casesChorea: 2/13 cases
Head tremor: 1/13 cases
Oculomotor apraxia 6/13 cases Present
Other ocular signs Strabism: 6/13 cases AbsentNystagmus: 3/13 cases
Tendon reflexes Absent: 9/13 cases BriskDecreased: 4/13 cases
Head tremor 4/13 cases Absent
Deep sensory loss 9/13 cases Absent
Cerebellar atrophy
Mild: 2/13 cases
ModerateModerate: 6/13 casesSevere: 3/13 cases
Not available: 2/13 cases
AFP level (ng/ml) 32.9 21.9
Figure  1.  a)  Family  tree  of  the  patient.  b)  Upper:  DNA sequence of  the  patient,
showing  the  heterozygous  form  of  the  exon  6  missense  mutation  c.502C>T
p.Arg168Trp.  Lower:  DNA sequence  of  the  healthy  individuals  c)  The  identified
aminoacid change is located within a highly conserved region of the protein
Figure  2.  Brain  MRI  of  the  patient,  sagittal  T1-weighted,  indicating  moderate
cerebellar atrophy

